Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.

Drug development performance is examined using data on clinical research projects of 10 pharmaceutical companies. In contrast to previous work on the discovery phase of pharmaceutical R&D we find a strong correlation between the diversity of firms' development efforts and the success probability of individual projects, but no effect of scale per se. Large firms' superior performance in drug development appears to be driven by returns to scope rather than returns to scale. Scope is confounded with firm fixed effects, however, suggesting an important role for inter-firm differences in the organization and management of the development function.

[1]  R. Willig,et al.  Economies of scope , 1981 .

[2]  Zvi Griliches,et al.  R&D, Patents, and Productivity , 1981 .

[3]  John C. Panzar,et al.  Technological determinants of firm and industry structure , 1989 .

[4]  John M. Vernon,et al.  Technical Change and Firm Size: The Pharmaceutical Industry , 1974 .

[5]  J. Glass,et al.  An empirical analysis of scale and scope economies and technical change in an Irish multiproduct banking firm , 1992 .

[6]  D. Teece.  ECONOMIES OF SCOPE AND THE SCOPE OF THE ENTERPRISE , 1980 .

[7]  E. Berndt,et al.  Scale and Scope Effects on Advertising Agency Costs , 1990 .

[8]  J. Schumpeter,et al.  Capitalism, Socialism and Democracy , 1943 .

[9]  David B. Audretsch,et al.  Innovation in Large and Small Firms: An Empirical Analysis , 1988 .

[10]  C. Freeman.  Economics of Industrial Innovation , 1975 .

[11]  John T. Scott,et al.  Market Structure and Technological Change , 1987 .

[12]  J. Schumpeter.  Capitalism, Socialism and Democracy , 1943 .

[13]  I. Cockburn,et al.  Scale, scope, and spillovers: the determinants of research productivity in drug discovery. , 1996, The Rand journal of economics.

[14]  L. R. Christensen,et al.  Economies of Density versus Economies of Scale: Why Trunk and Local Service Airline Costs Differ , 1984 .

[15]  Elizabeth J. Jensen.  Research Expenditures and the Discovery of New Drugs , 1987 .

[16]  Samuel B. Graves,et al.  Innovative productivity and returns to scale in the pharmaceutical industry , 1993 .

[17]  Wesley M. Cohen,et al.  Empirical studies of innovation and market structure , 1989 .

[18]  William S. Comanor,et al.  Research and Technical Change in the Pharmaceutical Industry , 1965 .

[19]  Keith Pavitt,et al.  The Size Distribution of Innovating Firms in the UK: 1945-1983 , 1987 .

[20]  D Schwartzman.  "Innovation in the Pharmaceutical Industry". , 1978, British medical journal.

[21]  Z. Griliches,et al.  Who Does R&D and Who Patents? , 1982 .

[22]  Constance E. Helfat,et al.  Know-how and asset complementarity and dynamic capability accumulation : The case of R&D , 1997 .

[23]  Nick von Tunzelmann,et al.  Patents and productivity: (The University of Chicago Press, 1984) pp. 512, [UK pound]15.25. (paperback edition, 1987.) , 1989 .

[24]  I. Cockburn,et al.  Measuring competence?: exploring firm effects in pharmaceutical research , 1994 .

[25]  K. Arrow.  Economic Welfare and the Allocation of Resources for Invention , 1962 .